Boehringer’s survodutide meets the Phase III cardiovascular safety endpoint in SYNCHRONIZE-CVOT, with improvements in weight, blood pressure and metabolic markers.
Written By: Saniya Katakdhond, PharmD
Reviewed By: Pharmacally Editorial Team
Boehringer Ingelheim’s investigational glucagon/GLP-1 dual receptor agonist survodutide (BI 456906) met the primary cardiovascular safety endpoint in the Phase III SYNCHRONIZE-CVOT trial. The findings showed that survodutide did not increase major adverse cardiovascular event (MACE) risk compared with placebo in adults with overweight or obesity and elevated cardiovascular risk. The study also reported improvements in several cardiometabolic measures, including systolic blood pressure, waist circumference, body weight and metabolic biomarkers.
SYNCHRONIZE-CVOT Establishes Cardiovascular Safety
Announced on November 9, 2026, the global, randomised, double-blind, placebo-controlled Phase III trial enrolled 5,530 adults with overweight or obesity and elevated cardiovascular risk. Eligible participants had established cardiovascular disease (CVD), chronic kidney disease (CKD), and/or at least two weight-related complications or cardiovascular risk factors.
Participants received once-weekly subcutaneous survodutide at doses of 3.6 mg or 6.0 mg, or placebo. The event-driven study evaluated the time to the first occurrence of its primary composite cardiovascular endpoint.
The trial met its primary endpoint under both the treatment-regimen and supplementary secondary estimands. Using the treatment-regimen estimand, survodutide demonstrated a hazard ratio (HR) of 0.89 (95% CI: 0.67–1.18; p<0.001 for non-inferiority) compared with placebo.
The five-point MACE composite included cardiovascular death, non-fatal myocardial infarction (MI), non-fatal stroke, ischaemia-related coronary revascularisation and heart failure events. The findings established that survodutide did not increase cardiovascular event risk within the prespecified non-inferiority framework.
A key secondary analysis also demonstrated non-inferiority for three-point MACE, comprising cardiovascular death, non-fatal MI and non-fatal stroke (HR 0.84; 95% CI: 0.60–1.18; p<0.0001).
Cardiometabolic Improvements Beyond Weight Reduction
Beyond cardiovascular safety, survodutide demonstrated improvements across several cardiometabolic measures at Week 72.
Using the supplementary secondary estimand, systolic blood pressure decreased by up to 6.68 mmHg with survodutide, compared with 1.76 mmHg with placebo (p=0.0001). Waist circumference decreased by up to 11.96 cm, compared with 2.74 cm in the placebo group.
Participants receiving survodutide also achieved weight reduction of up to 13.7%, compared with 2.0% with placebo. These findings were reported in a population with elevated cardiovascular risk, including individuals with type 2 diabetes.
Additional reductions in high-sensitivity C-reactive protein (hs-CRP) and triglycerides were reported compared with placebo, indicating improvements in inflammatory and lipid-related metabolic markers.
Importantly, the treatment-regimen estimand evaluates treatment effects regardless of treatment discontinuation or other relevant treatment changes, whereas the supplementary secondary estimand estimates the effect expected with continued treatment under specified assumptions. This distinction is relevant when interpreting the reported metabolic improvements alongside cardiovascular safety findings.
Gastrointestinal Events and Treatment Discontinuations
Gastrointestinal (GI) adverse events were the most commonly reported events with survodutide and were mostly mild to moderate in severity. Nausea, vomiting, diarrhoea and constipation occurred more frequently than with placebo.
Discontinuation due to GI adverse events occurred in 19.3% of participants receiving 3.6 mg survodutide and 20.8% receiving 6.0 mg, compared with 1.9% in the placebo group.
Most discontinuations occurred during dose escalation. The original protocol allowed limited flexibility for slower titration, dose adjustment or temporary treatment interruption, potentially contributing to discontinuations among participants who might otherwise have continued treatment.
To address tolerability, upcoming Phase IIIb studies, including SYNCHRONIZE-START, SYNCHRONIZE-HERA and ELEVATE-LIVER, alongside the Phase III SYNCHRONIZE-T2D study, are incorporating more flexible, patient-centred titration strategies.
Survodutide’s Clinical Development and Regulatory Outlook
The findings were presented at the American Heart Association (AHA) Scientific Sessions 2026 and simultaneously published in The Lancet on November 9, 2026.
Based on the totality of evidence generated across the SYNCHRONIZE programme, Boehringer Ingelheim is moving forward with global regulatory submissions for survodutide in obesity.
Beyond obesity, survodutide is being evaluated in the global Phase III LIVERAGE and LIVERAGE-Cirrhosis trials. These studies assess its efficacy and safety in adults with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis stages 2–3, and compensated MASH cirrhosis (fibrosis stage 4), respectively.
Survodutide remains investigational and has not been approved for any indication. Its efficacy and safety have not been established for routine clinical use.
Clinical Interpretation
SYNCHRONIZE-CVOT provides important Phase III evidence that survodutide did not increase major cardiovascular event risk compared with placebo in adults with overweight or obesity and elevated cardiovascular risk. Improvements in blood pressure, waist circumference, body weight and metabolic biomarkers further support the potential of dual glucagon/GLP-1 receptor agonism to address obesity-associated metabolic dysfunction.
However, cardiovascular non-inferiority should not be interpreted as evidence of cardiovascular risk reduction or superiority over placebo. Furthermore, the substantial rate of GI-related treatment discontinuations highlights a tolerability challenge that future titration strategies will need to address. The forthcoming regulatory review and additional clinical evaluation will help determine survodutide’s eventual role in obesity management.
References
Boehringer Ingelheim’s survodutide is the first glucagon/GLP-1 dual agonist to demonstrate a favourable cardiovascular safety profile in global Phase III SYNCHRONIZE-CVOT trial alongside significant cardiometabolic benefits, Boehringer Ingelheim, November 9, 2026.
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People with Overweight or Obesity (SYNCHRONIZE™ – CVOT), ClinicalTrials.gov ID NCT06077864
About the Writer
Saniya Sanjay Katakdhond (Linkedin) is a Doctor of Pharmacy professional with hands-on experience in patient case review, clinical documentation, medical record analysis, and patient care.
Her hospital experience has strengthened her understanding of clinical conditions, treatment approaches, and multidisciplinary healthcare practices.
With ICH-GCP certification and a research-oriented approach, she brings clinical insight and attention to detail to healthcare content development.
As a healthcare writer, Saniya focuses on translating clinical knowledge and patient-care experience into clear, accurate, and evidence-informed medical content.